Bogart Wealth LLC boosted its holdings in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 177.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,028 shares of the financial services provider’s stock after purchasing an additional 5,776 shares during the period. Bogart Wealth LLC’s holdings in iShares NASDAQ Biotechnology Index were worth $964,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IBB. Amarillo National Bank increased its holdings in shares of iShares NASDAQ Biotechnology Index by 200.0% during the fourth quarter. Amarillo National Bank now owns 2,784 shares of the financial services provider’s stock worth $297,000 after buying an additional 1,856 shares in the last quarter. Patriot Wealth Management Inc. acquired a new position in shares of iShares NASDAQ Biotechnology Index during the fourth quarter worth $4,650,000. White Lighthouse Investment Management Inc. acquired a new position in shares of iShares NASDAQ Biotechnology Index during the fourth quarter worth $1,417,000. Chesley Taft & Associates LLC increased its holdings in shares of iShares NASDAQ Biotechnology Index by 195.3% during the fourth quarter. Chesley Taft & Associates LLC now owns 40,776 shares of the financial services provider’s stock worth $4,354,000 after buying an additional 26,968 shares in the last quarter. Finally, F&V Capital Management LLC increased its holdings in shares of iShares NASDAQ Biotechnology Index by 200.0% during the fourth quarter. F&V Capital Management LLC now owns 6,183 shares of the financial services provider’s stock worth $660,000 after buying an additional 4,122 shares in the last quarter. Hedge funds and other institutional investors own 21.10% of the company’s stock.

Shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) opened at $110.91 on Thursday. The firm has a market capitalization of $10,350.00, a price-to-earnings ratio of 3.66 and a beta of 1.38. iShares NASDAQ Biotechnology Index has a 1-year low of $88.96 and a 1-year high of $114.17.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 22nd were issued a $0.125 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 0.45%. This is an increase from iShares NASDAQ Biotechnology Index’s previous quarterly dividend of $0.04. The ex-dividend date was Thursday, December 21st. iShares NASDAQ Biotechnology Index’s dividend payout ratio is presently 2.38%.

ILLEGAL ACTIVITY NOTICE: “iShares NASDAQ Biotechnology Index (IBB) Holdings Raised by Bogart Wealth LLC” was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/ishares-nasdaq-biotechnology-index-ibb-holdings-raised-by-bogart-wealth-llc/1802666.html.

iShares NASDAQ Biotechnology Index Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares NASDAQ Biotechnology Index (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.